Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract contains only journal subscription and informational content and does not present any research findings.

This study found that none of the depigmenting compounds tested in beef heifers produced a permanent depigmenting effect, though visible depigmentation lasted up to 3 months.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This review discusses the current status of genetic research on male-pattern hair loss and reports no new findings, outlining significant achievements and future challenges in understanding its biology and treatment.

This study reported that certain minoxidil conjugates, specifically those with spermine, methylenedianiline, and diaminofluorene, were able to induce differentiation in HL-60 acute myeloid leukemia cells without toxicity at a concentration of 10 μM.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

This study observed that dermatologists and physicians who frequently treat male pattern hair loss have practices and attitudes that may create a favorable care environment compared to less experienced physicians.

This study found that treatment with imipramine and pseudoephedrine can effectively restore antegrade ejaculation in diabetic patients suffering from retrograde ejaculation, offering potential fertility solutions through natural or assisted reproductive methods.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

This study concluded that male patients with improved lower urinary tract symptoms may have a lower risk of death, suggesting a potential benefit of treating symptoms beyond just managing patient discomfort.

This study identified several patient-specific factors that can predict both the likelihood of undergoing and failing a post-TURP void trial, aiding in the selection of candidates for immediate assessment.

This study suggests that any baldness, particularly moderate balding, is associated with a higher risk of fatal prostate cancer in men, supporting a possible link between hair loss and prostate cancer mechanisms.

MPZL3 protein affects hair growth cycles and could help manage hair loss.

This study found that cyclic MPA is as effective as OCPs in resuming ovulation among women with PCOS, offering a viable alternative for those who cannot or choose not to use OCPs.

This study identified robust susceptibility genes and potential drug candidates for male-pattern baldness, providing insights into the condition's molecular mechanisms.

This study found that medroxyprogesterone injections led to partial or complete hair regrowth in some Pomeranian dogs with alopecia X, though their IGF-1 levels remained unchanged.

This study found that MPEG-dihexPLA micelles significantly improved the skin deposition of tacrolimus compared to a marketed ointment, suggesting better targeted delivery with reduced systemic absorption.

This study found that a genetic model using SNPs can predict early-onset male-pattern baldness with moderate accuracy, which may assist in decisions about interventions.

This study found that topical application of bovine milk polar lipids accelerated hair cycle progression in mice, showing potential for use in cosmetic products.

This study found that finasteride treatment was effective for male pattern alopecia and that hair loss significantly impacted patients' quality of life and psychological well-being.

In this study, researchers found a significant association between the rs13405699 SNP at 2q31.1 and male pattern baldness among Han Chinese men, suggesting genetic influence on this condition in this population.

This study found that combining minoxidil and spironolactone was more effective for hair density and severity of hair loss in women with androgenic alopecia compared to minoxidil and finasteride, with no serious adverse effects reported.

In this study, 24 weeks of using Scalpoo® shampoo, containing ingredients like biotin and herbal compounds, significantly reduced hair shedding by 43.6% and increased hair thickness and count in patients with male and female pattern hair loss, as assessed by imaging and expert evaluations.

In this study, intradermal injection of botulinum toxin type A significantly increased hair count and improved physician-assessed hair condition in men with male pattern baldness after 24 weeks, with no serious adverse events reported beyond temporary local pain and redness.

This study found that isolated scalp microneedling did not improve scalp coverage or hair density in male pattern hair loss patients, with no adverse events reported.

This study identified MPB susceptibility genes and potential drug candidates that may help uncover molecular mechanisms and address male-pattern baldness.

This study found that gender-affirming hormone therapy in transgender men increased acne and male pattern hair loss, while in transgender women, it led to melasma and female pattern hair loss.

In this study, botulinum toxin type A injections reduced the severity of treatment-resistant scalp psoriasis in more patients compared to placebo over a 12-week period.

This study found that combining fractional radiofrequency microneedling with 5% topical minoxidil improved hair count and thickness more than minoxidil alone in Chinese men with male pattern hair loss.

This study found that mice lacking myelin protein zero-like 3 (Mpzl3) had reduced body weight and adiposity despite increased food intake, which was linked to higher energy expenditure and improved glycemic control.